Immunopterin: A prospective therapy and preventative to fight COVID-19?

IF 0.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Pteridines Pub Date : 2022-01-01 DOI:10.1515/pteridines-2022-0038

Phillip B. B. Moheno, D. Fuchs

{"title":"Immunopterin: A prospective therapy and preventative to fight COVID-19?","authors":"Phillip B. B. Moheno, D. Fuchs","doi":"10.1515/pteridines-2022-0038","DOIUrl":null,"url":null,"abstract":"Abstract Background The authors explore the therapeutic and prophylactic efficacies of Immunopterin (calcium pterin-6-carboxylate chelate) against coronavirus colds and as a therapy against COVID-19. Methods To determine Immunopterin’s therapeutic efficacy against colds and flus, a 5-year observational study was conducted with 34 subjects who took Immunopterin when feeling symptoms of a cold or flu. The mean sample cold recovery time was compared to the US population mean. A review of the Moheno (2014) 2-year observational study was conducted to evaluate the prophylactic efficacy of Immunopterin against colds. Early COVID-19 case studies, treated with Immunopterin, were collected to explore Immunopterin’s efficacy as a therapeutic and prophylactic against COVID19 disease. Results The mean cold recovery time for the therapeutic sample in the cold/flu observational study was 30 h compared to the US population mean of 168 h (N = 34; p < 0.001). Subjects taking prophylactic Immunopterin reported 0% incidences of colds and flus (N = 31). Immunopterin successfully treated four confirmed COVID-19 subjects. A fifth clinical nurse case study demonstrates COVID-19 prevention. Conclusions The therapeutic and prophylactic efficacies of Immunopterin against coronavirus colds, along with reported cross-reactivity between coronavirus colds and SARS-CoV-2 strongly suggest Immunopterin can act as a therapy and preventative against COVID- 19 infection associated disease.","PeriodicalId":20792,"journal":{"name":"Pteridines","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pteridines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/pteridines-2022-0038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Background The authors explore the therapeutic and prophylactic efficacies of Immunopterin (calcium pterin-6-carboxylate chelate) against coronavirus colds and as a therapy against COVID-19. Methods To determine Immunopterin’s therapeutic efficacy against colds and flus, a 5-year observational study was conducted with 34 subjects who took Immunopterin when feeling symptoms of a cold or flu. The mean sample cold recovery time was compared to the US population mean. A review of the Moheno (2014) 2-year observational study was conducted to evaluate the prophylactic efficacy of Immunopterin against colds. Early COVID-19 case studies, treated with Immunopterin, were collected to explore Immunopterin’s efficacy as a therapeutic and prophylactic against COVID19 disease. Results The mean cold recovery time for the therapeutic sample in the cold/flu observational study was 30 h compared to the US population mean of 168 h (N = 34; p < 0.001). Subjects taking prophylactic Immunopterin reported 0% incidences of colds and flus (N = 31). Immunopterin successfully treated four confirmed COVID-19 subjects. A fifth clinical nurse case study demonstrates COVID-19 prevention. Conclusions The therapeutic and prophylactic efficacies of Immunopterin against coronavirus colds, along with reported cross-reactivity between coronavirus colds and SARS-CoV-2 strongly suggest Immunopterin can act as a therapy and preventative against COVID- 19 infection associated disease.

查看原文本刊更多论文

免疫蝶呤:对抗COVID-19的前瞻性治疗和预防措施?

摘要背景探讨免疫蝶呤(6-羧酸螯合蝶呤钙)对冠状病毒感冒和COVID-19的治疗和预防作用。方法为确定免疫蝶呤治疗感冒和流感的疗效，对34名出现感冒或流感症状时服用免疫蝶呤的受试者进行了为期5年的观察研究。将平均样本冷恢复时间与美国人口平均值进行比较。对Moheno(2014)的2年观察性研究进行了回顾，以评估免疫蝶呤对感冒的预防效果。收集使用免疫蝶呤治疗的早期COVID-19病例研究，探讨免疫蝶呤作为治疗和预防COVID-19疾病的疗效。结果:在感冒/流感观察性研究中，治疗样本的平均感冒恢复时间为30小时，而美国人群的平均感冒恢复时间为168小时(N = 34;P < 0.001)。服用预防性免疫蝶呤的受试者报告感冒和流感的发生率为0% (N = 31)。免疫蝶呤成功治疗了4例新冠肺炎确诊患者。第五个临床护士案例研究展示了COVID-19的预防。结论免疫蝶呤对冠状病毒感冒的治疗和预防效果，以及已报道的冠状病毒感冒与SARS-CoV-2之间的交叉反应性，强烈提示免疫蝶呤可以作为一种治疗和预防COVID- 19感染相关疾病的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pteridines 生物-生化与分子生物学

CiteScore

1.20

自引率

25.00%

发文量

审稿时长

>12 weeks

期刊介绍： Pteridines is an open acess international quarterly journal dealing with all aspects of pteridine research. Pteridines are heterocyclic fused ring compounds involved in a wide range of biological functions from the color on butterfly wings to cofactors in enzyme catalysis to essential vitamins. Of the pteridines, 5,6,7,8-tetrahydrobiopterin is the necessary cofactor of several aromatic amino acid monoxygenases, the nitric oxide synthases and glyceryl ether monoxygenase (GEMO). Neopterin plays an essential role in the immune system and is an important biomarker in laboratory medicine for diseases such as HIV, cardiovascular disease, malignant tumors, among others. Topics: -Neopterin, dihydroneopterin, monapterin- Biopterin, tetrahydrobiopterin- Folates, antifolates, riboflavin- Phenylalanine, tyrosine, phenylketonuria, serotonin, adrenalin, noradrenalin, L-DOPA, dopamine, related biogenic amines- Phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase, nitric oxide synthases (iNOS), alkylglycerol monooxygenase (AGMO), dihydropterin reductase, sepiapterin reductase- Homocysteine, mediators of inflammation, redox systems, iron.